US FDA places partial clinical hold on Gilead’s studies on Magrolimab for AML treatment
The FDA action follows the previously announced discontinuation of the Phase 3 ENHANCE study of magrolimab in higher-risk…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.